These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4349107)

  • 41. [Influence of sodium alginate on the intestinal transit in low birth weight newborn infants].
    Chouraqui JP; Morer I; Renard P; Bielsky MC; Richard-Berthe C; Rambaud P
    Pediatrie; 1993; 48(6):473-7. PubMed ID: 8247649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
    Mandel KG; Daggy BP; Brodie DA; Jacoby HI
    Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins.
    Bilgin H; Eren A; Kara S
    Asia Pac J Clin Nutr; 2015; 24(4):753-5. PubMed ID: 26693761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The suppression of gastro-oesophageal reflux by alginates.
    Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
    Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Reflux esophagitis treated with Gaviscon].
    Sigstad H
    Tidsskr Nor Laegeforen; 1979 Nov; 99(33):1733-4. PubMed ID: 531861
    [No Abstract]   [Full Text] [Related]  

  • 46. The mode of action alginic acid compound in the reduction of gastroesophageal reflux.
    Malmud LS; Charkes ND; Littlefield J; Reilley J; Stern H; Rosenberg R; Fisher RS
    J Nucl Med; 1979 Oct; 20(10):1023-8. PubMed ID: 231639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Regurgitation esophagitis treated with Gaviscon].
    Jakobsen BM; Amdrup E
    Nord Med; 1968 Sep; 80(38):1243-5. PubMed ID: 4301892
    [No Abstract]   [Full Text] [Related]  

  • 48. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment].
    Maestri L
    Pediatr Med Chir; 2001; 23(3-4):187-9. PubMed ID: 11723856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisapride treatment for gastro-oesophageal reflux in children.
    Augood C; MacLennan S; Gilbert R; Logan S
    Cochrane Database Syst Rev; 2000; (3):CD002300. PubMed ID: 10908549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oesophageal disease in the elderly.
    Pelemans W; Vantrappen G
    Clin Gastroenterol; 1985 Oct; 14(4):635-56. PubMed ID: 2867841
    [No Abstract]   [Full Text] [Related]  

  • 52. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
    Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
    Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal-strength antacid.
    Castell DO; Dalton CB; Becker D; Sinclair J; Castell JA
    Dig Dis Sci; 1992 Apr; 37(4):589-93. PubMed ID: 1551350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative study of four antacids.
    Jacyna MR; Boyd EJ; Wormsley KG
    Postgrad Med J; 1984 Sep; 60(707):592-6. PubMed ID: 6091079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
    Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
    Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
    [No Abstract]   [Full Text] [Related]  

  • 56. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
    Chatfield S
    Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
    Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.
    Corvaglia L; Spizzichino M; Zama D; Aceti A; Mariani E; Legnani E; Faldella G
    Early Hum Dev; 2011 Dec; 87(12):775-8. PubMed ID: 21696897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
    Tytgat GN; Simoneau G
    Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reflux esophagitis treated with Gaviscon.
    Amdrup E; Jakobsen BM
    Acta Chir Scand Suppl; 1969; 396():16-7. PubMed ID: 5257679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.